21 Health Daily | Chairmen of Baiyunshan and Jiashitang Resign; Boan Biologics Expects H1 2024 Profit of No Less Than RMB 60 Million
Guangzhou Baiyunshan Pharmaceutical Holdings Company
Integrated Service Provider for Pharmaceuticals and Medical Devices
BoAn Biotech
Integrated Biopharmaceutical R&D and Manufacturing Company
Innovent
High-end Biologics Developer
Fosun Pharmaceutical
Healthcare Industry Group
HSGD
Ophthalmic Medical Device and Pharmaceutical R&D Developer
Source: 21st Century Business Herald
Policy Trends
NMPA Cosmetic Intelligence Declaration and Review System Successfully Passes the On-site Evaluation of Electronic Document Archiving and Management Pilot
Pharmaceutical and Medical Device Approval
Two Cell and Gene Therapy Products Proposed for Inclusion in Breakthrough Treatment Category
On July 22, the official website of the Center for Drug Evaluation (CDE) under the China National Medical Products Administration (NMPA) announced that two new drugs are proposed to be included in the breakthrough therapy designation. They are TAEST16001 Injection submitted by Guangdong Xiangxue Precision Medicine Technology Co., Ltd., and LX101 Injection submitted by Shanghai Langsheng Biotechnology Co., Ltd. The former is a TCR-T cell immunotherapy product intended for treating soft tissue sarcoma with HLA-A*02:01 tissue genotype and positive expression of tumor antigen NY-ESO-1; the latter is an AAV gene therapy drug for treating inherited retinal dystrophy (IRD) associated with RPE65 biallelic mutations.
Innovent Bio to Submit Marketing Application for Mazdutide in Diabetes Indication
On July 22, Innovent Bio announced that its dual agonist of glucagon-like peptide-1 receptor (GLP-1R)/glucagon receptor (GCGR), mazdutide (research code: IBI362), achieved the primary endpoint and all key secondary endpoints in the Phase 3 clinical study (DREAMS-1) conducted among Chinese subjects with type 2 diabetes. The study demonstrated comprehensive benefits in glycemic control, weight reduction, and cardiovascular-renal metabolic indicators.
Fosun Pharmaceutical's Subsidiary Receives Drug Registration Application Acceptance
On July 22, Fosun Pharmaceutical announced that the drug registration applications for Sodium Nitroprusside Injection and Flurbiprofen Axetil Injection from its holding subsidiary, Chongqing Yaoyou Pharmaceutical Co., Ltd., have been accepted by the National Medical Products Administration (NMPA).
Earnings Disclosure
Shandong BoAn Biotechnology Co. Ltd. Expects Profit for the First Half of the Year to Be No Less Than 60 Million Yuan
On July 22, BoAn Biotech announced that the group expects to record a profit of no less than RMB 60 million for the six months ended June 30, 2024, compared to a loss of approximately RMB 119 million for the six months ended June 30, 2023. The group achieved a turnaround from loss to profit during the reporting period, mainly due to the continuous increase in the number of patients covered by its first product, Boyono, leading to steady growth in sales revenue. Additionally, the group's second product, Boyouble, as the first domestically produced denosumab injection in China, experienced rapid growth during the reporting period, contributing significantly to the overall performance.
Capital Market
HSGD Completes New Round of Financing
Recently, HSGD (Suzhou) Biomedical Technology Co., Ltd., a leading innovator in glaucoma medical devices in China, has completed a new round of financing. This round was led by Guohai Innovation Capital, with participation from the Suzhou Industrial Park Science and Technology Innovation Fund. The funds will primarily be used to advance the scaled production and commercialization of the company's glaucoma intraocular pressure monitoring product, HaiSiWei®. HSGD is progressively establishing itself as a comprehensive solution provider centered around glaucoma patients, integrating preoperative screening, intraoperative treatment, and postoperative intraocular pressure management.
Unmagnatech Completes Over 100 Million Yuan in Series A+ Financing
Recently, the innovative medical device product independently developed by Weici Technology - the world's first 128-channel liquid helium-free magnetoencephalography (MEG) system, Marvel MEG® (Beijing Medical Device Registration Certificate No. 20242070378), has been successfully approved for marketing. This product is the MEG system with the highest number of channels globally that does not require liquid helium. Weici Technology also announced the completion of an over RMB100 million Series A+ round of financing. This round was led by the Beijing Robotics Industry Fund, with participation from CAS Star, existing shareholder LMF Venture Capital, Zhongguancun Science City, Minyin International, and Yarui Capital. To date, Weici Technology has completed five rounds of financing totaling over RMB300 million in the four years since its establishment.
Akeso Appoints Wang Bingzhong as Chief Financial Officer
On July 22, Akeso Biopharma announced that Dr. Bing C. WANG (Wang Bingzhong) has been appointed as the company's Chief Financial Officer. Wang Bingzhong has many years of experience in global strategic investment, corporate financing, financial management, and business development in the biopharmaceutical field. Prior to this, he served as the Chief Financial Officer at Cellectis S.A., a French biopharmaceutical company dedicated to developing CAR-T cell and cancer immunotherapies based on a gene-editing platform.
Cachet Pharmaceutical Co.,Ltd. Chairman Xu Wenli Departs from Position
On July 22, Cachet Pharmaceutical Co., Ltd. announced that Chairman Wenli Xu had submitted his resignation to the company's board of directors due to a work adjustment within the group. He will step down from his positions as chairman, director, and chairman of the strategy committee. After resigning from the above positions, Wenli Xu will no longer hold any position in the company or its subsidiaries.
Chairman of Guangzhou Baiyunshan Pharmaceutical Holdings Company Resigns, Vice Chairman Yang Jun Takes Over as Acting Chairman
On July 22, Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited announced that the board of directors had received a written resignation report from Li Chuyuan, the company's chairman, on the same day. Due to personal reasons, Li Chuyuan resigned from his positions as chairman of the 9th board of directors, executive director, and director of the Strategic Development and Investment Committee of the board. After his resignation, Li Chuyuan will no longer hold any position in the company. Li Chuyuan confirmed that he has no disagreement with the company’s board of directors, and there are no other matters that need to be brought to the attention of the company's shareholders. Vice Chairman Yang Jun will temporarily perform the duties of the chairman until a new chairman is elected by the board.
Sailong Pharmaceutical's Shareholder Sailong Juzhi Plans to Reduce Stake by No More Than 1%
On July 22, Sailong Pharmaceutical announced that Zhuhai Hengqin New Area Sailong Juzhi Investment Co., Ltd., a shareholder holding 8.25% of the company, plans to reduce its shares in the company by no more than 1.76 million shares (1% of the company's total share capital) through centralized bidding within three months after 15 trading days from the date of the announcement.
